Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group.
Seki R, Ohshima K, Nagafuji K, Fujisaki T, Uike N, Kawano F, Gondo H, Makino S, Eto T, Moriuchi Y, Taguchi F, Kamimura T, Tsuda H, Ogawa R, Shimoda K, Yamashita K, Suzuki K, Suzushima H, Tsukazaki K, Higuchi M, Utsunomiya A, Iwahashi M, Imamura Y, Tamura K, Suzumiya J, Yoshida M, Abe Y, Matsumoto T, Okamura T. Seki R, et al. Among authors: fujisaki t. Int J Hematol. 2010 Mar;91(2):258-66. doi: 10.1007/s12185-009-0475-2. Int J Hematol. 2010. PMID: 20066574
Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study).
Nagafuji K, Miyamoto T, Eto T, Kamimura T, Taniguchi S, Okamura T, Ohtsuka E, Yoshida T, Higuchi M, Yoshimoto G, Fujisaki T, Abe Y, Takamatsu Y, Yokota S, Akashi K, Harada M. Nagafuji K, et al. Among authors: fujisaki t. J Hematol Oncol. 2013 Feb 6;6:14. doi: 10.1186/1756-8722-6-14. J Hematol Oncol. 2013. PMID: 23388549 Free PMC article.
Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04).
Murayama T, Fukuda T, Okumura H, Sunami K, Sawazaki A, Maeda Y, Tsurumi H, Uike N, Hidaka T, Takatsuka Y, Eto T, Tsuda H, Fujisaki T, Miyamoto T, Tsuneyoshi N, Iyama S, Nagafuji K, Harada M. Murayama T, et al. Among authors: fujisaki t. Int J Hematol. 2016 Jun;103(6):676-85. doi: 10.1007/s12185-016-1976-4. Epub 2016 Mar 21. Int J Hematol. 2016. PMID: 27084252 Clinical Trial.
Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
Henzan H, Takase K, Kamimura T, Mori Y, Yoshimoto G, Iwasaki H, Nagafuji K, Ogawa R, Eto T, Uchida N, Fujisaki T, Kato K, Minami M, Kikushige Y, Akashi K, Miyamoto T; Fukuoka Blood & Marrow Transplantation Group (FBMTG). Henzan H, et al. Among authors: fujisaki t. Int J Hematol. 2020 Sep;112(3):349-360. doi: 10.1007/s12185-020-02911-z. Epub 2020 Jun 10. Int J Hematol. 2020. PMID: 32524309
Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
Seki R, Ohshima K, Fujisaki T, Uike N, Kawano F, Gondo H, Makino S, Eto T, Moriuchi Y, Taguchi F, Kamimura T, Tsuda H, Ogawa R, Shimoda K, Yamashita K, Suzuki K, Suzushima H, Tsukazaki K, Higuchi M, Utsunomiya A, Iwahashi M, Imamura Y, Tamura K, Suzumiya J, Yoshida M, Abe Y, Matsumoto T, Okamura T. Seki R, et al. Among authors: fujisaki t. Cancer Sci. 2009 Oct;100(10):1842-7. doi: 10.1111/j.1349-7006.2009.01268.x. Epub 2009 Jul 1. Cancer Sci. 2009. PMID: 19656156 Free PMC article.
Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.
Miyamoto T, Nagafuji K, Fujisaki T, Uchida N, Matsue K, Henzan H, Ogawa R, Takase K, Aoki T, Hidaka M, Teshima T, Taniguchi S, Akashi K, Harada M; Japan Study Group for Cell Therapy and Transplantation (JSCT). Miyamoto T, et al. Among authors: fujisaki t. Int J Hematol. 2018 Apr;107(4):468-477. doi: 10.1007/s12185-017-2389-8. Epub 2017 Dec 14. Int J Hematol. 2018. PMID: 29243031 Clinical Trial.
Correction to: Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
Henzan H, Takase K, Kamimura T, Mori Y, Yoshimoto G, Iwasaki H, Nagafuji K, Ogawa R, Eto T, Uchida N, Fujisaki T, Kato K, Minami M, Kikushige Y, Akashi K, Miyamoto T; Fukuoka Blood & Marrow Transplantation Group (FBMTG). Henzan H, et al. Among authors: fujisaki t. Int J Hematol. 2020 Sep;112(3):431-432. doi: 10.1007/s12185-020-02932-8. Int J Hematol. 2020. PMID: 32643074
Predictors of impaired antibody response after SARS-CoV-2 mRNA vaccination in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
Mori Y, Uchida N, Harada T, Katayama Y, Wake A, Iwasaki H, Eto T, Morishige S, Fujisaki T, Ito Y, Kamimura T, Takahashi T, Imamura Y, Tanimoto K, Ishitsuka K, Sugita J, Kawano N, Tanimoto K, Yoshimoto G, Choi I, Hidaka T, Ogawa R, Takamatsu Y, Miyamoto T, Akashi K, Nagafuji K. Mori Y, et al. Among authors: fujisaki t. Am J Hematol. 2023 Jan;98(1):102-111. doi: 10.1002/ajh.26769. Epub 2022 Oct 31. Am J Hematol. 2023. PMID: 36260658 Free PMC article.
252 results